QB3
4
15M
3
0.19
0.25
- Areas of investment
Summary
In 2000 was created QB3, which is appeared as Corporate Investor. The main department of described Corporate Investor is located in the San Francisco. The venture was found in North America in United States.
The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2017. The usual things for fund are deals in the range of 50 - 100 millions dollars.
Among the various public portfolio startups of the fund, we may underline Pionyr Immunotherapeutics For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Sex Tech, Biotechnology. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
The usual cause for the fund is to invest in rounds with 6 partakers. Despite the QB3, startups are often financed by SV Health Investors, OrbiMed, OUP (Osage University Partners). The meaningful sponsors for the fund in investment in the same round are Vida Ventures, Stephen Hoffman, Sofinnova Investments. In the next rounds fund is usually obtained by Kevin Moore, Creative Ventures, Berkeley SkyDeck.
Investments analytics
Analytics
- Total investments
- 4
- Lead investments
- 0
- Rounds per year
- 0.19
- Follow on index
- 0.25
- Investments by industry
- Biotechnology (3)
- Health Care (3)
- Genetics (2)
- Bioinformatics (2)
- Pharmaceutical (1) Show 9 more
- Investments by region
-
- United States (4)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 92M
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Mission Bio | 27 Jun 2018 | Biotechnology, Health Care, Genetics, Bioinformatics | Early Stage Venture | United States, California, San Francisco |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.